Advances in lncRNAs from stem cell-derived exosome for the treatment of cardiovascular diseases

Cardiovascular diseases (CVDs) are the leading cause of mortality globally. Benefiting from the advantages of early diagnosis and precision medicine, stem cell-based therapies have emerged as promising treatment options for CVDs. However, autologous or allogeneic stem cell transplantation imposes a...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 986683
Main Authors Ma, Jiahui, Lei, Pengyu, Chen, Haojie, Wang, Lei, Fang, Yimeng, Yan, Xiaoqing, Yang, Qinsi, Peng, Bo, Jin, Libo, Sun, Da
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 06.09.2022
Subjects
acellular therapy
cardiovascular diseases
exosome
lncRNA
Pharmacology
stem cells
Online AccessGet full text

Cover

More Information
Summary:Cardiovascular diseases (CVDs) are the leading cause of mortality globally. Benefiting from the advantages of early diagnosis and precision medicine, stem cell-based therapies have emerged as promising treatment options for CVDs. However, autologous or allogeneic stem cell transplantation imposes a potential risk of immunological rejection, infusion toxicity, and oncogenesis. Fortunately, exosome can override these limitations. Increasing evidence has demonstrated that long non-coding RNAs (lncRNAs) in exosome from stem cell paracrine factors play critical roles in stem cell therapy and participate in numerous regulatory processes, including transcriptional silencing, transcriptional activation, chromosome modification, and intranuclear transport. Accordingly, lncRNAs can treat CVDs by directly acting on specific signaling pathways. This mini review systematically summarizes the key regulatory actions of lncRNAs from different stem cells on myocardial aging and apoptosis, ischemia-reperfusion injury, retinopathy, atherosclerosis, and hypertension. In addition, the current challenges and future prospects of lncRNAs treatment for CVDs are discussed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology
Reviewed by: Xiangqi Li, Naval Medical University, China
Edited by: Xiaoyong Tong, Chongqing University, China
These authors have contributed equally to this work
Ying Xin, Jilin University, China
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.986683